PR+ cells add prognostic value in luminal A breast cancer

December 17, 2012
PR+ cells add prognostic value in luminal A breast cancer
Semiquantitative immunohistochemical expression of progesterone receptor-positive tumor cells improves prediction of survival within luminal A breast cancers, according to a study published online Dec. 10 in the Journal of Clinical Oncology.

(HealthDay)—Semiquantitative immunohistochemical expression of progesterone receptor-positive tumor cells improves prediction of survival within luminal A breast cancers, according to a study published online Dec. 10 in the Journal of Clinical Oncology.

Aleix Prat, M.D., from the University of North Carolina at Chapel Hill, and colleagues analyzed gene expression and pathologic features in primary tumors across five independent cohorts to improve current immunohistochemical subtyping of genomically defined luminal A and B subtypes. The researchers derived and independently tested optimal cut-offs of percentage of PR positive tumor cells to predict survival.

The researchers found that in luminal A tumors there were consistently higher rates of PR positivity, human 2 (HER2) negativity, and histologic grade 1, compared to B subtypes. Luminal A tumors also had significantly higher quantitative PR gene and . Independent of endocrine therapy administration, an empiric cut-off of more than 20 percent of PR-positive tumor cells was significant for predicting survival differences within immunohistochemical-defined luminal A tumors. The immunohistochemical 4 score had no additional prognostic value within hormonal receptor (HR) positive/HER2-negative disease when intrinsic immunohistochemical-based subtypes were used that included more than 20 percent PR-positive

"Semiquantitative immunohistochemical expression of PR adds prognostic value within the current immunohistochemical-based luminal A definition by improving the identification of good outcome breast cancers," the authors write. "The new proposed immunohistochemical-based definition of luminal A tumors is HR positive/HER2 negative/Ki-67 less than 14 percent, and PR more than 20 percent."

Several authors disclosed financial ties to BioClassifier.

Explore further: Older patients with certain breast cancer subtype may not benefit from radiation therapy

More information: Abstract
Full Text (subscription or payment may be required)
Editorial

Related Stories

Breast cancer recurrence defined by hormone receptor status

October 1, 2012

Human epidermal growth factor (HER2) positive breast cancers are often treated with the same therapy regardless of hormone receptor status. New research published in BioMed Central's open access journal Breast Cancer Research ...

Recommended for you

Men face higher risk of cancers linked to oral sex

February 13, 2016

Men are twice as likely as women to get cancer of the mouth and throat linked to the human papillomavirus, or HPV, one of the most common sexually transmitted infections, researchers say.

Scientists find leukemia's surroundings key to its growth

February 10, 2016

Researchers at The University of Texas at Austin have discovered that a type of cancer found primarily in children can grow only when signaled to do so by other nearby cells that are noncancerous. The finding, published in ...

Study examines evolution of cancer

February 8, 2016

A novel Yale study answers age-old questions about how cancers spread by applying tools from evolutionary biology. The new insights will help scientists better understand the genetic origins of tumor metastases, and lead ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.